Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / GOSS - Gossamer Bio Announces Data Presentations at the American College of Allergy Asthma and Immunology Annual Scientific Meeting 2019


GOSS - Gossamer Bio Announces Data Presentations at the American College of Allergy Asthma and Immunology Annual Scientific Meeting 2019

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that two abstracts supporting GB001, the Company’s oral DP2 antagonist for the treatment of asthma and allergic disease, have been accepted for presentation at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting 2019 being held November 7- 11 in Houston, Texas.

Details for the ACAAI presentations are as follows:

 

Session Title:

E-posters – Meet the Authors: Session 1

Abstract Number:

P210

Abstract Title:

Indicators of Asthma Exacerbation Before Initiation of Biologic Therapy: A Real-world Experience

Presenter Name:

Hector Ortega, MD, ScD

Presentation Date/Time:

Friday, November 8; 5:30 – 5:45 p.m. CT

Location:

George R. Brown Convention Center, Halls A3 & B3 (Level 3), Monitor 8

 

Session Title:

E-posters – Meet the Authors: Session 2

Abstract Number:

P213

Abstract Title:

Phase 2 study results of DP2-antagonist GB001 on asthma worsening and other asthma control markers

Presenter Name:

Hector Ortega, MD, ScD

Presentation Date/Time:

Saturday, November 9; 11:45 a.m. – 12:00 p.m. CT

Location:

George R. Brown Convention Center, Halls A3 & B3 (Level 3), Monitor 8

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191108005080/en/

For Investors:
Argot Partners
Tel 212.600.1902
gossamerbio@argotpartners.com

For Media:
Argot Partners
David Rosen
Tel 212.600.1902
david.rosen@argotpartners.com

Copyright Business Wire 2019
Stock Information

Company Name: Gossamer Bio Inc.
Stock Symbol: GOSS
Market: NYSE
Website: gossamerbio.com

Menu

GOSS GOSS Quote GOSS Short GOSS News GOSS Articles GOSS Message Board
Get GOSS Alerts

News, Short Squeeze, Breakout and More Instantly...